Actor
Ajmal Ameer is an Indian actor working in Malayalam & Tamil Film Industry. He was a doctor before he became an actor. Ajmal Ameer has qualified in medicine from National Pirogov Memorial Medical University, Vinnytsya City, Ukraine and has plans to open a hospital in the near future. Now, he is enjoying his stint as an actor and wants to be known as a good one in acting. His first movie was "Pranayakalam", opposite Vimala Raman. His second film was a Tamil film called Anjathe. Luck struck for him in his Third film, as he got to work with Superstar Mohanlal in Madambi, as Mohanlal's younger brother. Among his projects, his Malayalam film Madambi is very special to Ajmal, as it gave him a chance to share screen space with superstar Mohanlal. He also worked on a few important projects in Tamil and Malayalam. One was TN-07 AL4777, a remake of the Hindi film Taxi No. 9211. Ajmal played John Abraham's role in the film, while Pasupathi donned the role of Nana Patekar.
| Movie | Director | Release Date |
|---|---|---|
| Mysskin | May 2026 | |
| Prabhu Srinivas | 01 Aug 2025 | |
| Venkat | Aug 2025 | |
| Ratheesh Raghunandan | 07 Mar 2024 |
| Name | Ajmal Ameer |
| Profession(s) | |
| Date Of Birth | |
| Birth Place | |
| Current Residence | |
| Religion | |
| Nationality | |
| Height | |
| Zodiac Sign | |
| Hobbies | |
Ajmal Ameer Net Worth |
|
| Net Worth | |
The most recent movies for Ajmal Ameer is Accused.
Pisasu 2 were Ajmal Ameer's upcoming films.
Ajmal Ameer's next feature film with Mysskin.
The images featured on this page are sourced from publicly available platforms, official press releases, and promotional materials. These images are published strictly for editorial, informational, and news reporting purposes under the principles of fair use.
We do not claim ownership of any images unless explicitly stated. All image copyrights belong to their respective photographers, production houses, or copyright holders.
If you are the rightful owner of any image and believe that its use on this website is unauthorized or objectionable, please contact us ([email protected]) with proper details. We will promptly review and remove the content if required.